本帖最后由 老马 于 2012-1-13 21:20 编辑
! ~: e, P: u0 f( w; |7 k' X s L- o. s# [
爱必妥和阿瓦斯丁的比较. @& L. e' { X9 E
2 S/ C: n. ~3 {+ i+ q
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/3 B% U0 P; g$ y: Z$ J
( l" F( a1 ^. l# ?. N( z# r9 `/ Z
9 x# h9 R9 V |3 W5 X0 c. Bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
( X5 u/ X) P/ \9 W==================================================
5 v8 m0 B% O( r9 I7 ^Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% a! _+ D1 ]8 U- [ @3 C; w
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
~4 A8 _% I5 C) E9 e5 W! S. f" RResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- \! k8 u- Z/ m
|